Dissemin is shutting down on January 1st, 2025

Published in

Galenos Yayinevi, Turkish Journal of Hematology, 4(30), p. 387-39393, 2013

DOI: 10.4274/tjh.2012.0135

Links

Tools

Export citation

Search in Google Scholar

Evaluation of the Safety of Imatinib Mesylate in 200 Iraqi Patients with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Study

Journal article published in 2013 by Bassam Francis Matti ORCID, Alaadin Sahham Naji, Alaa Fadhil Alwan
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Question mark in circle
Preprint: policy unknown
Upload
Question mark in circle
Postprint: policy unknown
Upload
Question mark in circle
Published version: policy unknown
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Objective: Imatinib mesylate, a tyrosine kinase inhibitor, is presently the drug of choice for chronic myeloid leukemia (CML). During therapy, a few patients may develop hematological and non-hematological adverse effects.